^
8d
New P1 trial
|
CD4 (CD4 Molecule)
|
Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
12d
Enrollment closed • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
cisplatin • carboplatin • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
12d
Enrollment closed
|
PD-L1 (Programmed death ligand 1)
|
Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
18d
New P2 trial
|
carboplatin • paclitaxel • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
22d
Enrollment closed
|
PD-L1 (Programmed death ligand 1)
|
cisplatin • carboplatin • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
1m
R3767-ONC-2011: Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma (clinicaltrials.gov)
P3, N=1546, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2025 --> Mar 2026
Enrollment closed • Trial primary completion date
|
Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
2ms
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
P2, N=120, Not yet recruiting, Regeneron Pharmaceuticals | Trial completion date: Nov 2029 --> Dec 2030 | Initiation date: Mar 2025 --> Mar 2026 | Trial primary completion date: Apr 2027 --> Jun 2028
Trial completion date • Trial initiation date • Trial primary completion date • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
2ms
New P2 trial
|
capecitabine • oxaliplatin • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
3ms
New P2 trial
|
cisplatin • carboplatin • pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
3ms
Trial completion date • Trial primary completion date
|
cisplatin • carboplatin • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
3ms
New P2 trial
|
Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
5ms
New P2 trial • Minimal residual disease
|
Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)